In "Pain Control: COX-2-Selective NSAIDs" by Rob Hutchison (March 2004), the details of the author's financial disclosure were omitted. Hutchison was paid honoraria by Ligand Pharmaceuticals, a manufacturer of opioids, none of which is mentioned in the article, and by Pfizer, Inc., manufacturer of Celebrex and Bextra, two drugs discussed in the article. Hutchison also owns stock in Pfizer.

In "Managing Atrial Fibrillation" (News, March 2004) highlights were listed from the new American College of Physicians guidelines on the treatment of newly detected atrial fibrillation in most adults. Among these was ". . . using (when cardioversion is desired) either transthoracic echocardiography with anticoagulation therapy (except when there is intracardiac thrombus) or delayed cardioversion and anticoagulation therapy." Instead of transthoracic, it should have read transesophageal.

In "Forensic Nursing" by Ann Wolbert Burgess, Anne Dunn Berger, and Rachel R. Boersma (March 2004) an article that was cited misspelled the name of the author. Reference number 12 should have read "Finnie H. Slipping through the cracks. On the edge 2003;9(4):10-3."